Reduction in HPV 16/18 Prevalence Among Young Women Following HPV Vaccine Introduction in a Highly Vaccinated District, Japan, 2008-2017

Overview

Journal J Rural Med

Date 2019 Jun 14

PMID 31191766

Citations 9

Authors

Akihiro Karube

Fumiko Saito

Enami Nakamura

Akihiro Shitara

Natsuki Ono

Megumi Konno

Daisuke Tamura

Daisuke Nagao

Affiliations

Soon will be listed here.

Abstract

Human papillomavirus (HPV) vaccination was introduced in Japan in April 2013, as a national immunization program for girls aged 12-16 years, after an initial introduction in 2010 as a public-aid program for girls aged 13-16 years. The Yuri-Honjo district had the highest vaccine coverage among women aged 17-51 years in 2017, due to the original public-aid program. The aim of this study was to evaluate the differences in the vaccine types of HPV16/18 infections between 2008-2012 (pre-vaccine era) and 2013-2017 (vaccine era). We evaluated whether HPV vaccination was associated with a decrease in the prevalence of HPV16/18 and high-risk HPV and the incidence of HPV-associated cervical lesions. A total of 1,342 women aged 18-49 years, covering both the pre-vaccine and vaccine eras, who visited Yuri Kumiai General Hospital and underwent HPV genotype tests from June 2008 to December 2017 were compared. Among women aged 18-24 years with higher vaccine coverage (68.2%), the prevalence of HPV16/18 and high-risk HPV decreased from 36.7% and 69.4%, respectively, in the pre-vaccine era to 5.8% and 50.0%, respectively, in the vaccine era (p=0.00013 and p=0.047, respectively). Among those with cervical intraepithelial neoplasia grade 2- and grade 2+, HPV16/18 prevalence decreased from 30.0% to 2.7% (p=0.0018) and from 81.8% to 36.4% (p=0.030), respectively. In this age group, the rate of HPV16/18 positivity decreased significantly. Among age groups with lower vaccine coverage, HPV prevalence did not significantly differ between the two eras. The prevalence of HPV16/18 and high-risk HPV significantly decreased in women aged 18-24 years, most of whom were vaccinated. HPV vaccination effectively reduced the prevalence of HPV16/18 infections in the Yuri-Honjo district.

Citing Articles

Prevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021-2023.

Sharipova I, Musabaev E, Sadirova S, Suyarkulova D, Tashev S, Akhmedova S J Gynecol Oncol. 2025; 36(1):e7.

PMID: 39900340 PMC: 11790988. DOI: 10.3802/jgo.2025.36.e7.

Prevalence and genotype distribution of HPV combined with cervical pathological results in women from Sichuan, China: A cross-sectional study based on post-vaccination period 2019 to 2023.

Mo B, Ye Y, Yu M, Tong X, Cao H, Du C Cancer Med. 2024; 13(16):e70148.

PMID: 39189602 PMC: 11348228. DOI: 10.1002/cam4.70148.

Genital and Oral HPV Geno-Prevalence Measured through Urine and Saliva Samples in Young Adults in Italy.

Napolitano F, Angelillo S, Bianco A, Di Giuseppe G, Di Onofrio V, Licata F Vaccines (Basel). 2024; 12(2).

PMID: 38400188 PMC: 10892725. DOI: 10.3390/vaccines12020205.

HPV vaccination status and effectiveness in Korean women with HPV16/18 infection (2010-2021): a retrospective study.

Na Y, Jeong O, Seong J, Lee J, Lee S, Hur S J Gynecol Oncol. 2024; 35(5):e56.

PMID: 38330379 PMC: 11390253. DOI: 10.3802/jgo.2024.35.e56.

Prevalence of Human Papillomavirus Types 16/18 and Effect of Vaccination among Japanese Female General Citizens in the Vaccine Crisis Era.

Kitamura T, Suzuki M, Shigehara K, Fukuda K, Matsuyama T, Kume H Viruses. 2023; 15(1).

PMID: 36680199 PMC: 9863140. DOI: 10.3390/v15010159.

References

Karube A, Sasaki M, Tanaka H, Nakagome O, Dahiya R, Fujimoto S . Human papilloma virus type 16 infection and the early onset of cervical cancer. Biochem Biophys Res Commun. 2004; 323(2):621-4. DOI: 10.1016/j.bbrc.2004.08.142. View

Villa L, Costa R, Petta C, Andrade R, Ault K, Giuliano A . Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5):271-8. DOI: 10.1016/S1470-2045(05)70101-7. View

Khan M, Castle P, Lorincz A, Wacholder S, Sherman M, Scott D . The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst. 2005; 97(14):1072-9. DOI: 10.1093/jnci/dji187. View

Stevens M, Garland S, Tabrizi S . Human papillomavirus genotyping using a modified linear array detection protocol. J Virol Methods. 2006; 135(1):124-6. DOI: 10.1016/j.jviromet.2006.02.007. View

Harper D, Franco E, Wheeler C, Moscicki A, Romanowski B, Roteli-Martins C . Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006; 367(9518):1247-55. DOI: 10.1016/S0140-6736(06)68439-0. View

Inoue M, Sakaguchi J, Sasagawa T, Tango M . The evaluation of human papillomavirus DNA testing in primary screening for cervical lesions in a large Japanese population. Int J Gynecol Cancer. 2006; 16(3):1007-13. DOI: 10.1111/j.1525-1438.2006.00460.x. View

. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007; 356(19):1915-27. DOI: 10.1056/NEJMoa061741. View

Paavonen J, Jenkins D, Bosch F, Naud P, Salmeron J, Wheeler C . Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007; 369(9580):2161-2170. DOI: 10.1016/S0140-6736(07)60946-5. View

Nielsen A, Kjaer S, Munk C, Iftner T . Type-specific HPV infection and multiple HPV types: prevalence and risk factor profile in nearly 12,000 younger and older Danish women. Sex Transm Dis. 2007; 35(3):276-82. DOI: 10.1097/OLQ.0b013e31815ac5c7. View

10.

Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P . Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008; 68(1):307-13. DOI: 10.1158/0008-5472.CAN-07-2754. View

11.

Stevens M, Garland S, Tabrizi S . Validation of an automated detection platform for use with the roche linear array human papillomavirus genotyping test. J Clin Microbiol. 2008; 46(11):3813-6. PMC: 2576620. DOI: 10.1128/JCM.01169-08. View

12.

Descamps D, Hardt K, Spiessens B, Izurieta P, Verstraeten T, Breuer T . Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin. 2009; 5(5):332-40. DOI: 10.4161/hv.5.5.7211. View

13.

Wheeler C, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Perez G . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis. 2009; 199(7):936-44. DOI: 10.1086/597309. View

14.

Brown D, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009; 199(7):926-35. DOI: 10.1086/597307. View

15.

Onuki M, Matsumoto K, Satoh T, Oki A, Okada S, Minaguchi T . Human papillomavirus infections among Japanese women: age-related prevalence and type-specific risk for cervical cancer. Cancer Sci. 2009; 100(7):1312-6. PMC: 11158131. DOI: 10.1111/j.1349-7006.2009.01161.x. View

16.

Paavonen J, Naud P, Salmeron J, Wheeler C, Chow S, Apter D . Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-14. DOI: 10.1016/S0140-6736(09)61248-4. View

17.

Cuzick J . Long-term cervical cancer prevention strategies across the globe. Gynecol Oncol. 2010; 117(2 Suppl):S11-4. DOI: 10.1016/j.ygyno.2010.01.025. View

18.

Munoz N, Kjaer S, Sigurdsson K, Iversen O, Hernandez-Avila M, Wheeler C . Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010; 102(5):325-39. DOI: 10.1093/jnci/djp534. View

19.

Konno R, Tamura S, Dobbelaere K, Yoshikawa H . Prevalence and type distribution of human papillomavirus in healthy Japanese women aged 20 to 25 years old enrolled in a clinical study. Cancer Sci. 2011; 102(4):877-82. PMC: 11158349. DOI: 10.1111/j.1349-7006.2011.01878.x. View

20.

Kahn J, Brown D, Ding L, Widdice L, Shew M, Glynn S . Vaccine-type human papillomavirus and evidence of herd protection after vaccine introduction. Pediatrics. 2012; 130(2):e249-56. PMC: 3408690. DOI: 10.1542/peds.2011-3587. View